The HeartMate II (HMII) is the most popular continuous-flow left ventricular assist device (CF-LVAD) employed worldwide. Implantation of CF-LVADs has been associated with high rates of gastrointestinal bleeding, particularly from arteriovenous malformations (AVMs) [1, 2] . Part of the increased bleeding risk relates to a reduction in circulating von Willebrand factor multimers [3] . However, it has also long been hypothesized that loss of the physiologic pulse, as occurs with CF-LVAD placement, may lead to hemodynamic changes in the gastrointestinal mucosa that are ultimately "angiodysplasia-genic" [4] . A 65-year-old man with no previous history of AVMs or gastrointestinal hemorrhage underwent uncomplicated implantation of a HMII device. He presented to the hospital 5 weeks postimplantation with frank hematochezia. After stabilization, he underwent both upper and lower gastrointestinal endoscopic evaluations, which revealed several large cecal AVMs with stigmata of recent bleeding (• " Fig. 1 ), as well as numerous gastric antral AVMs without signs of bleeding. These AVMs were treated successfully with argon plasma coagulation (APC) therapy. He also underwent video capsule endoscopy, which revealed a single 4-mm, nonbleeding AVM in the jejunum, which was not treated. Once he had been stabilized, the patient was discharged home. He re-presented to the hospital 4 weeks later with recurrent gastrointestinal bleeding. Repeat upper gastrointestinal endoscopy revealed the presence of two large gastric AVMs with active bleeding (• " Fig. 2 ), which were treated with APC. Of note, these two AVMs had not been present on the previous endoscopy 4 weeks earlier. Despite treatment, the patient continued to experience gastrointestinal bleeding.
99 m Technetium-labeled red blood cell scintigraphy was performed, which revealed active bleeding in the jejunum consistent with the previously visualized AVM (• " Fig. 3 ). Given the recurrent and diffuse nature of his AVMs across the entire gastrointestinal tract, he was treated with systemic pharmacologic therapy using octreotide. His gastrointestinal bleeding finally ceased after this octreotide therapy. He remains free of recurrent hemorrhage several months later.
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